Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development of a novel human derived probiotic species platform - Phase 1

Project description

A human-derived probiotic platform

The probiotics market is growing worldwide due to the exciting potential of next-generation probiotics (NGPs) for the prevention and treatment of specific diseases. Whereas traditional probiotics are mainly derived from non-human origins with limited positive effects, NGPs are human-derived and play a key role in a healthy microbiota. However, the development of NGP products needs new advanced techniques of cultivation and production. The EU-funded NOVOBIOME-1 project proposes a platform that covers the entire cycle of NGP production by applying innovative patterns and technological processes to accelerate the procedure to reach the market. The project will study the prerequisites to maximise commercialisation in the European market.

Objective

The global probiotics market is flourishing and anticipated to grow substantially in the coming years due the highly promising application of next-generation probiotics (NGPs) as live biotherapeutic products (LBPs). Whereas traditional probiotics are mainly derived from non-human origins with limited positive effects, NGPs are human-derived and play a key role in a healthy microbiota. All major probiotic companies are now moving into this field, however they are struggling with product development due to the intrinsic properties of NGPs. As a result, no NGP products have successfully reached the market yet. NGP product development requires radically new techniques for cultivation and production. This untapped market segment is highly attractive for Winclove. To tackle this problem, Winclove is developing the NOVOBIOME platform – covering the full cycle of NGP product development. Winclove’s approach leverages its already functional in-house facilities and infrastructure and combines it with innovative models and technological methods that can fast-track the timeline of NGP product to market for our clients. Winclove, an innovative Dutch SME, is a leader in microbiota-management, which has
been offering services in research, development and manufacturing of probiotic formulations for over 25 years. Winclove has been very successful in growing the company into a sustainable business with 73 FTE, growing 14% per annum on average. It provides its services to over 80 customers in 35 countries worldwide. As such, it has sold via its clients over 130 million daily dosages in 2018. Winclove aims to provide the NOVOBIOME platform as a B2B fee for service to dedicated innovative companies that are working on NGP-based LBPs. Winclove anticipates to generate €8M in turnover within the first 5 years of commercializing the NOVOBIOME platform. This SME-1 instrument project NOVOBIOME phase 1 enables Winclove to investigate the requirements to maximize the European commercialization

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

WINCLOVE BV
Net EU contribution
€ 50 000,00
Address
HULSTWEG 11
1032 LB AMSTERDAM
Netherlands
SME
Yes
Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00